Role of zoledronic acid in the prevention and treatment of osteoporosis.

Räkel, Agnès; Boucher, Andrée; Ste-Marie, Louis-Georges

Räkel, Agnès; Boucher, Andrée; Ste-Marie, Louis-Georges.

Affiliation

Räkel A; Department of Medicine, Centre de recherche du CHUM, Université de Montréal, Hôpital Saint-Luc, Montréal, QC, Canada.

Clin Interv Aging ; 6: 89-99, 2011.

Article in En | MEDLINE | ID: mdl-21594000

Subject(s)

Bone Density Conservation Agents/pharmacology; Bone Density Conservation Agents/therapeutic use; Diphosphonates/pharmacology; Diphosphonates/therapeutic use; Imidazoles/pharmacology; Imidazoles/therapeutic use; Osteoporosis/drug therapy; Age Factors; Aging/pathology; Bone Density/drug effects; Bone Density Conservation Agents/adverse effects; Clinical Trials as Topic; Diphosphonates/adverse effects; Fractures, Bone/prevention & control; Humans; Imidazoles/adverse effects; Injections, Intravenous; Osteoporosis, Postmenopausal/drug therapy; Risk Factors; Sex Factors; Zoledronic Acid

Key words

elderly; osteoporosis; zoledronic acid

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis / Diphosphonates / Bone Density Conservation Agents / Imidazoles Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Interv Aging Journal subject: GERIATRIA Year: 2011 Document type: Article Affiliation country: Canada Country of publication: New Zealand

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google